Us Bancorp \De\ Immunovant, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Immunovant, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,699 shares of IMVT stock, worth $46,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,699

Previous 2,295 25.97%

Holding current value

$46,739

Previous $60,000 23.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$27.51 - $27.51 $16,395 - $16,395	-596 Reduced 25.97%	1,699 $46,000
Q2 2024 Aug 06, 2024	SELL	$25.1 - $31.61 $6,049 - $7,618	-241 Reduced 9.5%	2,295 $60,000
Q1 2024 May 07, 2024	SELL	$30.27 - $43.79 $16,073 - $23,252	-531 Reduced 17.31%	2,536 $81,000
Q4 2023 Feb 09, 2024	BUY	$31.31 - $44.19 $2,410 - $3,402	77 Added 2.58%	3,067 $129,000
Q3 2023 Nov 03, 2023	BUY	$18.55 - $39.96 $575 - $1,238	31 Added 1.05%	2,990 $114,000
Q2 2023 Aug 09, 2023	SELL	$14.2 - $23.75 $610 - $1,021	-43 Reduced 1.43%	2,959 $56,000
Q1 2023 May 09, 2023	BUY	$15.27 - $19.72 $656 - $847	43 Added 1.45%	3,002 $46,000
Q4 2022 Feb 13, 2023	BUY	$6.59 - $17.75 $10,425 - $28,080	1,582 Added 114.89%	2,959 $52,000
Q3 2022 Oct 27, 2022	BUY	$3.93 - $6.37 $2,872 - $4,656	731 Added 113.16%	1,377 $8,000
Q2 2022 Aug 01, 2022	BUY	$3.38 - $5.65 $37 - $62	11 Added 1.73%	646 $3,000
Q1 2022 May 11, 2022	SELL	$5.06 - $8.77 $1,528 - $2,648	-302 Reduced 32.23%	635 $3,000
Q4 2021 Feb 11, 2022	SELL	$7.33 - $9.32 $842 - $1,071	-115 Reduced 10.93%	937 $8,000
Q3 2021 Nov 10, 2021	BUY	$7.01 - $11.37 $7,374 - $11,961	1,052 New	1,052 $9,000

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account